慢性心力衰竭患者阿托伐他汀治疗前后血清MMP-9和C反应蛋白的变化及意义被引量：1

下载PDF

导出

摘要 90例慢性心力衰竭(CHF)患者(心功能Ⅱ级27例,心功能Ⅲ级35例,心功能Ⅳ级28例)随机分成常规治疗组和阿托伐他汀治疗组,检测两组治疗前后血清基质金属蛋白酶-9(MMP-9)和C反应蛋白(CRP)水平变化,并与30例健康人比较。结果心功能Ⅱ、Ⅲ、Ⅳ级组的血清MMP-9和CRP均显著高于正常对照组,Ⅳ级组显著高于Ⅲ级组,Ⅲ级组显著高于Ⅱ级组(P均<0.05)。阿托伐他汀组治疗后较常规治疗组MMP-9和CRP显著降低(P<0.05)。认为血清MMP-9和CRP增高可作为估测CHF患者心功能不全程度的指标,他汀类药物可降低CHF患者血清MMP-9和CRP水平。

作者陶志刚徐雁王洪敏

机构地区青岛大学医学院附属烟台毓璜顶医院

出处《山东医药》 CAS 北大核心 2008年第46期43-44,共2页 Shandong Medical Journal

关键词心力衰竭基质金属蛋白酶 C反应蛋白干预治疗

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy [ J ]. Circulation, 1998,97 ( 17 ) : 1708-1715.
2符明龙,卢竞前.辛伐他汀治疗扩张型心肌病[J].国外医学（心血管疾病分册）,2005,32(6):367-369. 被引量：3
3杨来宝,吴润桂,李志雄,单守杰.辛伐他汀联合苯那普利干预充血性心力衰竭的作用[J].中国煤炭工业医学杂志,2005,8(10):1054-1056. 被引量：5
4Crisby M, Nordin-Fredriksson G, Shah PK,et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization [ J ]. Circulation, 2001, 103(7): 926-933.
5Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activationand chemokine expression in vascular smooth muscle cells and mononuclear cella [ J]. Athemscleresis, 1999,147(2) :253-261.

二级参考文献25

1Pryor WA, Squadrito GL. The chemistry of peroxynitite: A product from the reaction of nitricoxide with superoxide[J]. Am J Physol, 1995, 268:L699.
2Cohn JN. The management of chronic heart failure[J]. N Engl Med, 1996, 335: 490-498.
3Bonetti PO, Lerman LO, Napolic, et al. Statin effects beyond lipid cowering- are they clinically relevant? [J]. Eur Heart J, 2003,24: 225-248.
4Levine B, Kalmn J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in congestive heart failure [ J ]. N Engl J Med, 1990, 323: 236.
5Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure[J]. Circulation, 2001,103:2303-2309.
6Nickening G, Baumer AT, Temur Y, et al. Statin sensitive dysregulated AT - I receptor function and density in hypercholedterolemic men[J ]. Circulation, 2001, 104: 576-581.
7Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin Ⅱ - induced cardiac injury by a 3 - hydroxy- 3 - methylglutaryl coenzyme a reeducate inhibition[J]. Circulation, 2001, 104:576-581.
8Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Racl- Gtpase and represent a target for statin treament[J]. Circulation, 2003, 108:1567-1574.
9Nodek, Fujita M, Kitakaze M, et al. Short - term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardio - myopathy[J]. Circulation, 2003, 108: 839-843.
10Laufs V, Fata VL, Liao JK, et al. Inhibition of 3 - hydroxy- 3-methylglutaryl (HMG) -CoA reductase blocks hypoxiamediated down regulation of endothelial nitric oxide synthase[J]. J Biol Chem, 1997, 272: 31725-31729.